Drug recall · August 1, 2018
Valsartan and Hydrochlorothiazide recall
Why: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 320 mg/12.5 mg tablets, USP, 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2318-19
- Lots / codes
Lot Numbers: 1191185M, 1191186M, 1225615M, 1233948M, 1250718M, 1253257M
- Quantity
- 64,168 bottles
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Product was distributed throughout the United States, including Hawaii and Puerto Rico
- Initiated
- July 16, 2018 · Voluntary: Firm initiated
- Classified
- July 24, 2018
- Reported
- August 1, 2018
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.